- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00404339
Vaccine Therapy in Treating Patients With Head and Neck Cancer
Adjuvant p53 Peptide Loaded DC-Based Therapy for Subjects With Squamous Cell Cancer of the Head and Neck (A Phase I Safety and Immunogenicity Trial)
RATIONALE: Vaccines made from a person's dendritic cells mixed with peptides may help the body build an effective immune response to kill tumor cells.
PURPOSE: This randomized phase I trial is studying the side effects of vaccine therapy in treating patients with head and neck cancer.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
OBJECTIVES:
Primary
- Determine the toxicity of intranodally injected autologous dendritic cells (DC) loaded with wild-type p53 peptides with or without T-helper peptide epitope in patients with squamous cell carcinoma of the head and neck.
Secondary
- Determine the local and systemic immunomodulatory effects of this vaccine in these patients.
OUTLINE: This is a randomized, pilot study.
Patients undergo leukapheresis. The resulting dendritic cells (DC) are pulsed with wild-type (wt) p53 peptides with or without T-helper (Th) peptides. Individual autologous vaccines are prepared for each patient. Patients who are HLA-A2-DR4-negative are randomized to 1 of 2 treatment arms (arm I or arm II). Patients who are HLA-A2-DR4-positive are assigned to arm III.
- Arm I: Patients receive autologous DC loaded with HLA-A2.1-restricted wt p53 peptides only.
- Arm II: Patients receive autologous DC loaded with HLA-A2.1-restricted wt p53 peptides and Th tetanus toxoid peptide.
- Arm III (HLA-A2-DR4-positive patients only): Patients receive autologous DC loaded with HLA-A2.1-restricted wt p53 peptides and Th wt p53 peptide.
In all arms, each vaccine is administered by ultrasonography-guided inguinal intranodal injection over 30 minutes on days 0, 14, and 28.
After completion of study therapy, patients are followed periodically.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- UPMC Cancer Centers
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically confirmed squamous cell carcinoma of the head and neck
- Resectable disease
- Any stage allowed
- Successfully treated with curative intent
Recurrent disease allowed provided the following criteria are met:
- No evidence of disease
- At least 6 weeks since prior antitumor therapy
Positive for HLA-A2.1
- HLA-DR4 allele status known
- Tumor tissue must be available
- No active brain metastases
PATIENT CHARACTERISTICS:
- ECOG performance status 0 or 1
- Life expectancy ≥ 6 months
- Granulocyte count > 2,500/mm^3
- Lymphocyte count > 700/mm^3
- Platelet count > 100,000/mm^3
- Bilirubin < 0.2 mg/dL
- Creatinine < 0.2 mg/dL
- Hemoglobin > 8 g/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception for ≥ 1 week before, during, and for ≥ 2 weeks after study completion
- No systemic infection or coagulation disorders
- No psychiatric disturbances that would preclude obtaining informed consent or safe conduct of protocol
- HIV negative
- Hepatitis B surface antigen and hepatitis C antibody negative
- No other active malignancies
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
At least 6 weeks since prior adjuvant radiotherapy or chemoradiotherapy
- No time restriction for prior curative therapy
- No concurrent pharmacological doses of steroids in any form (topical or systemic)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
|---|
|
Toxicity profile and overall toxicity rates
|
|
Immunologic response rate as measured by ELISPOT assay prevaccination and at days 14 and 18
|
|
Biologic response rate
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Robert L. Ferris, MD, PhD, University of Pittsburgh
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
- tilbakevendende metastatisk plateepitelkreft med okkult primær
- metastatisk plateepitelkreft med okkult primært plateepitelkarsinom
- stadium III plateepitelkarsinom i leppe og munnhule
- stadium IV plateepitelkarsinom i leppe og munnhule
- tilbakevendende plateepitelkarsinom i leppe og munnhule
- stadium III plateepitelkarsinom i orofarynx
- stadium IV plateepitelkarsinom i orofarynx
- tilbakevendende plateepitelkarsinom i orofarynx
- stadium III plateepitelkarsinom i nasopharynx
- stadium IV plateepitelkarsinom i nasopharynx
- tilbakevendende plateepitelkarsinom i nasopharynx
- stadium III plateepitelkarsinom i hypopharynx
- stadium IV plateepitelkarsinom i hypopharynx
- tilbakevendende plateepitelkarsinom i hypopharynx
- stadium III plateepitelkarsinom i strupehodet
- stadium IV plateepitelkarsinom i strupehodet
- tilbakevendende plateepitelkarsinom i strupehodet
- stadium III plateepitelkarsinom i paranasal sinus og nesehulen
- stadium IV plateepitelkarsinom i paranasal sinus og nesehulen
- tilbakevendende plateepitelkarsinom i paranasal sinus og nesehulen
- stadium I plateepitelkarsinom i leppe og munnhule
- stadium II plateepitelkarsinom i leppe og munnhule
- stadium I plateepitelkarsinom i paranasal sinus og nesehulen
- stadium II plateepitelkarsinom i paranasal sinus og nesehulen
- stadium I plateepitelkarsinom i hypopharynx
- stadium I plateepitelkarsinom i strupehodet
- stadium I plateepitelkarsinom i nasopharynx
- stadium I plateepitelkarsinom i orofarynx
- stadium II plateepitelkarsinom i hypopharynx
- stadium II plateepitelkarsinom i strupehodet
- stadium II plateepitelkarsinom i nasopharynx
- stadium II plateepitelkarsinom i orofarynx
- tungekreft
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- PCI-03-156
- CDR0000515081 (Registeridentifikator: PDQ (Physician Data Query))
- PCI-0507062
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .